For immediate release |
28 April 2014 |
Futura Medical plc
("Futura" or "the Company")
Block Listing Update
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology announces that, in the six months since the previous block admission update in October 2013 the following changes have taken place:
Futura Medical plc Option Plan |
Block Listed 2011-2013 |
Block Listing Brought Forward |
Options Exercised in Period |
Re-classified |
Block Listing Carried Forward |
|
|
|
|
|
|
Unapproved Share Option Scheme |
2,008,383 |
1,878,114 |
(100,000) |
8,321 |
1,786,435 |
|
|
|
|
|
|
EMI Share Option Scheme |
2,996,617 |
1,889,127 |
(52,500) |
(8,321) |
1,828,306 |
|
|
|
|
|
|
|
5,005,000 |
3,767,241 |
(152,500) |
- |
3,614,741 |
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive
|
Tel: +44 (0)1483 685 670 |
mail to: james.barder@futuramedical.com |
|
|
|
Nominated Adviser: |
|
N+1 Singer Aubrey Powell / Joe Stroud |
Tel:+44 (0)20 7496 3000 |
|
|
For media enquiries please contact: |
|
|
|
Buchanan |
|
Mark Court / Fiona Henson / Sophie Cowles |
Tel: +44 (0)20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.